BON Announced Next-Gen of Tea Pigment Digestive Health Products and Cooperation Agreement of US$26 Million with Beijing Huahai Keyuan
Rhea-AI Summary
Bon Natural Life (NASDAQ: BON) announced a non-exclusive 36-month cooperation agreement with Beijing Huahai Keyuan valued at US$26 million to sell and distribute BON's second-generation tea pigment digestive health products in Greater China, effective Nov 25, 2025.
BON describes tea pigments as a next-generation functional ingredient and reports that its proprietary Eurotium cristatum fermentation process increased digestive health activity by more than 200% versus first-generation formulations. The company plans broader global commercialization and said the deal supports potential revenue and earnings growth over time.
Positive
- Binding 36-month distribution contract valued at US$26 million
- Reported digestive activity improvement of more than 200% versus prior formulations
- Targeted launch in Greater China via an established distributor
Negative
- Agreement is explicitly non-exclusive, limiting market control
- Contract term 36 months may constrain long-term revenue visibility
Insights
BON signed a 36-month,
BON will supply second-generation tea pigment ingredients processed via a controlled biotransformation using an optimally selected Eurotium cristatum fermentation strain. The agreement with Beijing Huahai Keyuan covers distribution and sales across Greater China for a
Risk factors include the non-exclusive nature of the contract and reliance on a single distributor for regional rollout; market adoption depends on demonstrated consumer uptake and repeat purchases. The claim of digestive activity improvement of more than
Watch for three concrete signals over the next 12–36 months: reported shipment volumes or revenue milestones tied to the
Tea pigments, a key bioactive complex derived from tea, possess a strong scientific profile across lipid regulation, glycemic control, antioxidant function, and gastrointestinal support. As a next-generation functional tea ingredient, tea pigments represent the most significant innovation in the sector since the commercialization of tea polyphenols. Current market adoption is being driven primarily by two fast-growing segments: digestive wellness and blood-glucose management. With broad applicability and favorable consumer demand trends, tea pigments are positioned as a potential blockbuster ingredient with an anticipated market opportunity exceeding
As a global leading innovator in tea pigment ingredients, BON has identified that targeted biotransformation of tea raw materials can significantly enhance the functional performance of tea pigments. Leveraging this, BON undertook systematic research utilizing its proprietary, optimally selected Eurotium cristatum strain as a fermentation agent. Through a controlled biotransformation process — a precision-optimized fermentation method designed to strengthen functional attributes — BON believes it has achieved a substantial improvement in the digestive health benefits of tea pigments.
Testing demonstrates that the digestive health activity of BON's latest tea pigment product has increased by more than
Hu Yongwei, CEO and Chairman of BON, stated: "Through our strategic partnership with Huahai Keyuan, BON will leverage its competitive strengths and continued innovation in tea pigment technology to accelerate our expansion into the rapidly growing premium digestive health market. This agreement marks the next phase of BON's strategic development and positions us to drive synergistic growth across the digestive health sector. We also plan to introduce our innovative second-generation tea pigment product portfolio to global markets. BON believes this partnership will support meaningful revenue and earnings growth over time and further enhance long-term shareholder value."
About Bon Natural Life Limited ("BON")
BON is a
For more information, please contact:
Cindy Liu | IR
Email: bonnatural@appchem.cn
Safe Harbor Statement
This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes,""expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
View original content:https://www.prnewswire.com/news-releases/bon-announced-next-gen-of-tea-pigment-digestive-health-products-and-cooperation-agreement-of-us26-million-with-beijing-huahai-keyuan-302625751.html
SOURCE Bon Natural Life Limited
FAQ
What did BON announce on Nov 25, 2025 regarding a distribution agreement?
How much is the BON and Huahai Keyuan cooperation agreement worth for BON (NASDAQ: BON)?
What efficacy improvement did BON report for its second-generation tea pigment product?
Where will Huahai Keyuan distribute BON's tea pigment products under the agreement?
Does the BON distribution agreement give exclusive rights to Huahai Keyuan?
How might the US$26 million contract affect BON's 2026 revenue outlook?
